STAAR Surgical Company — Form 10-K Summary
Reporting period: Fiscal year ended December 30, 2016. The filing includes unaudited fourth-quarter data and comparable fiscal 2015 results. STAAR designs, manufactures, and sells implantable lenses and delivery systems for refractive and cataract surgery. The company operates as one ophthalmic surgical products segment and generated approximately 88% of sales outside the United States.
Financial Performance and Position
| Metric | Fiscal 2016 | Fiscal 2015 | Change |
|---|
| Net sales | $82.4 million | $77.1 million | +6.9% |
| Gross profit | $58.4 million | $52.7 million | +10.7% |
| Gross margin | 70.8% | 68.4% | +2.4 percentage points |
| Operating loss | $(12.7) million | $(5.3) million | Loss increased |
| Net loss | $(12.1) million | $(6.5) million | Loss increased |
| Net loss per share | $(0.30) | $(0.17) | Loss increased |
| Operating cash flow | $1.0 million | $(2.2) million | Improved |
| Capital expenditures | $3.2 million | $2.0 million | Increased |
- Revenue mix: ICL sales were $59.1 million, or 71.7% of sales, up 14.7% year over year. IOL sales were $19.7 million, or 23.9%, down 0.8%. Other surgical product sales were $3.6 million, or 4.4%, down 36.8%.
- Profitability: Gross margin benefited from the higher-margin ICL product mix, higher average selling prices, and improved ICL manufacturing costs. Operating expenses rose substantially, including research and development expense of $20.3 million, up 37.5%.
- Unusual expense: A February 2016 change-in-control provision accelerated vesting of all unvested equity awards and resulted in a $6.9 million non-cash stock-based compensation charge.
- Liquidity: Cash and cash equivalents were $14.0 million at year-end, compared with $13.4 million in 2015. Working capital was $28.8 million versus $31.2 million in 2015.
- Debt and obligations: The company had approximately $4.3 million outstanding under a Japanese line of credit, with no remaining availability. Capital lease obligations totaled approximately $2.5 million, and total contractual obligations were $15.4 million.
- Balance sheet: Total assets were $65.4 million, total liabilities were $27.5 million, and stockholders’ equity was $37.9 million. Pension plans were underfunded by approximately $4.0 million.
- Working capital metrics: Accounts receivable were $16.3 million, with DSO of 72 days. Inventory was $14.8 million, with finished-goods days on hand of 216 days.
Fourth-Quarter Results
| Metric | Q4 2016 | Q4 2015 |
|---|
| Net sales | $22.1 million | $20.9 million |
| Gross profit | $15.9 million | $14.7 million |
| Net loss | $(0.2) million | $(0.8) million |
| Net loss per share | Approximately $(0.00) | $(0.02) |
Material Changes and Management Outlook
- ICL growth was led by Asia-Pacific and Europe, including China sales growth of 35%, Japan growth of 51%, and Germany growth of 46%. Korea ICL sales declined 8%.
- IOL unit sales declined 6%; U.S. silicone IOL sales decreased following discontinuation of that product line.
- Management expects double-digit ICL unit growth over the following twelve months, excluding the United States and Korea, and expects 2017 gross margin to exceed 2016 levels.
- Management expects 2017 IOL sales to be generally similar to 2016, excluding the impact of the discontinued U.S. silicone IOL line. Total operating expenses may trend above 2016 levels.
- The company expects approximately $0.5 million of FDA remediation expense in 2017, compared with approximately $1.9 million in 2016.
- Strategic priorities include completing the quality-system remediation, expanding ICL adoption and surgeon training, strengthening clinical and regulatory capabilities, and developing premium ICL and IOL products, including extended-depth-of-field designs.
Risks, Contingencies, and Unusual Items
- FDA remediation: The 2014 FDA Warning Letter and 2015 FDA-483 identified quality-system and documentation deficiencies at the Monrovia facility. Until FDA concerns are resolved, approval of related Class III products may be withheld. The U.S. TICL application remained pending, and approval timing was uncertain.
- Customer concentration: Shanghai Langsheng accounted for approximately 19.4% of 2016 consolidated sales. Loss or underperformance of this distributor could materially reduce revenue.
- International exposure: Foreign currency movements, regulatory requirements, reimbursement changes, political conditions, and reliance on independent distributors affect results. The company does not actively hedge foreign currency exposure.
- Manufacturing concentration: Most ICL and IOL production occurs at the Monrovia facility, creating disruption risk from regulatory issues, natural disasters, equipment failures, or other events.
- Legal proceedings: A securities class action concerning alleged disclosures about regulatory violations was pending; class certification was granted in January 2017. A shareholder derivative action was dismissed in January 2017, but the plaintiff filed an appeal. No loss was accrued because potential losses were not estimable.
- Tax assets: The company had approximately $136.1 million of U.S. federal net operating loss carryforwards, but maintained a full valuation allowance because near-term utilization was uncertain.
- Going-forward funding: Management stated that cash balances and operating cash flow should meet foreseeable needs, but continued losses or unexpected expenditures could require additional financing.
- Audit and controls: BDO USA, LLP issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. Management concluded that disclosure controls and internal controls were effective.
Investor Verification Checklist
- Verify progress and FDA acceptance of the Monrovia remediation plan, including the status of the TICL PMA supplement.
- Assess whether projected double-digit ICL growth is being achieved, particularly in China, Japan, Europe, Korea, and other established markets.
- Monitor the impact of the discontinued U.S. silicone IOL line and the company’s ability to stabilize IOL sales.
- Review customer and distributor concentration, especially Shanghai Langsheng’s approximately 19% contribution to sales.
- Track operating cash flow, inventory levels, capital lease obligations, and the maturity or renewal of the $4.3 million Japanese credit facility.
- Evaluate whether increased marketing, clinical, quality, and research spending can translate into sustainable profitability.
- Review developments in the securities class action, derivative litigation appeal, pension funding, and other unquantified contingencies.
